[Does multiple myeloma response to induction therapy depend on plasma cell IL6 receptor gene expression?].

Background: Interleukine 6 (IL-6) is the most important cytokine involved in malignant plasma cells growth and survival.

Aim: To analyse bone marrow plasma cells IL6 receptor gene expression in both multiple myeloma patients at diagnosis and healthy bone marrow donors.

Methods: Clinical and biological patients' features and responses to Dexamethasone-Thalidomide induction therapy were gathered.